Volume 60, Issue 1, Pages 83-86 (July 2001) Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway  Jan Gossmann, M.D., Ralf Burkhardt, Sebastian Harder, Tomas Lenz, Annette Sedlmeyer, Ute Klinkhardt, Helmut Geiger, Ernst-Heinrich Scheuermann  Kidney International  Volume 60, Issue 1, Pages 83-86 (July 2001) DOI: 10.1046/j.1523-1755.2001.00773.x Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 1 Mean arterial pressure in healthy volunteers during a six-hour placebo or angiotensin II (Ang II) infusion without and with pretreatment with valsartan, an Ang II subtype 1 receptor (AT1R) blocker. Symbols are: (□) placebo; (•) Ang II; (▾) Ang II + valsartan; *P < 0.01 vs. placebo. Data are represented as mean ± SEM. Kidney International 2001 60, 83-86DOI: (10.1046/j.1523-1755.2001.00773.x) Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 2 Erythropoietin (EPO) plasma levels in healthy volunteers following a six-hour placebo or Ang II infusion without and with pretreatment with valsartan, an AT1R blocker. Symbols are: (□) placebo; () Ang II; () Ang II + valsartan; *P = 0.01 vs. placebo. Data are represented as mean ± SEM. Kidney International 2001 60, 83-86DOI: (10.1046/j.1523-1755.2001.00773.x) Copyright © 2001 International Society of Nephrology Terms and Conditions